학술논문

Retrospective observational analysis of bevacizumab (BV) plus paclitaxel (TXL) as first line treatment in metastatic HER2 negative breast cancer (BC): are BV long responders a different subgroup?
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 21 2016, 27 1p. Supplement: 4
Subject
Language
English
ISSN
15698041